



Effect of Lipohypertrophy on Accuracy of Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Diabetes Care 2015;38:e166–e167 | DOI: 10.2337/dc15-1267

Daniel J. DeSalvo,¹ David M. Maahs,² Laurel Messer,² R. Paul Wadwa,² Shelby Payne,¹ Trang T. Ly,^{1,3} and Bruce A. Buckingham¹

Repeated delivery of insulin in the same location induces a local reaction in the subcutaneous adipose tissue, often leading to lipohypertrophy (1,2). Advanced lipohypertrophy leads to slower, erratic insulin absorption due to the fibrous, relatively avascular nature of the tissue (3). Although lipohypertrophied tissue is commonly used for continuous glucose monitoring (CGM) sensor sites, the effect on sensor performance is unknown. Therefore, we analyzed the accuracy of sensors used simultaneously in lipohypertrophied and normal tissue.

In this prospective, multicenter study, subjects with type 1 diabetes and lipohypertrophy (≥ 3 cm diameter) were instructed to wear two Dexcom G4 Platinum sensors simultaneously: one in lipohypertrophied tissue and the second in normal tissue for 2 consecutive weeks. This procedure was then repeated on each subject with new sensors being worn simultaneously for a second 2-week period. Blood glucose (BG) readings from Bayer CONTOUR NEXT meters served as reference (4), with absolute relative difference (ARD) defined as the percent error between sensor and matched BG values. Only data from the first 7 days of sensor life were used in the analysis. The Mann-Whitney *U* test was used to compare the accuracy of the

sensors in lipohypertrophied versus normal tissue. Results are presented as mean \pm SD or median (interquartile range [25th%, 75th%]).

Twenty-nine subjects enrolled in the study. Baseline characteristics included 48% men, age of 29.6 ± 8.9 years, duration of diabetes of 17.3 ± 9.1 years, and hemoglobin A_{1c} of $7.5 \pm 0.8\%$ (58 ± 8.7 mmol/mol). The average diameter of lipohypertrophy was 8.1 ± 3.5 cm.

In total, there were 89,853 sensor glucose values between 40 and 400 mg/dL (range of sensor) with 1,547 corresponding BG readings. The median ARD for sensors in lipohypertrophied tissue was 10.0% (4.3, 17.2) versus 11.0% (4.9, 19.3) in normal tissue ($P < 0.001$). For BG ≤ 70 mg/dL, mean absolute difference (MAD) for sensors in lipohypertrophied tissue was 15 mg/dL ($n = 49$) compared with 18 mg/dL ($n = 48$) in normal tissue ($P = 0.14$). For BG ≥ 250 mg/dL, median ARD was 9.8% (4.6, 15.8) ($n = 341$) for sensors in lipohypertrophied tissue compared with 9.6% (4.8, 16.4) ($n = 334$) in normal tissue ($P = 0.44$) (Table 1).

In this analysis, CGM sensors in lipohypertrophied tissue showed equal or slightly superior accuracy to sensors in normal tissue. This was evident across all glucose ranges, with an overall median

ARD of 10.0% for sensors in lipohypertrophied tissue.

The question remains as to whether sensors cause harm to the skin or subcutaneous tissue by repeated insertions in the same area. Although nothing is infused at sensor sites, the insertion and subsequent movement of the sensor tip might induce acute local trauma and possibly more chronic skin reactions (5). However, our data suggest that the flow of interstitial fluid is not adversely affected by the lipohypertrophied tissue.

To our knowledge, this is the first study evaluating the effect of lipohypertrophy on CGM performance. Our results suggest that lipohypertrophy does not adversely impact sensor accuracy. Further work is needed to quantify the potential risks of sensor use in areas of lipohypertrophy over longer periods of time.

Acknowledgments. The authors acknowledge JDRF (grant 17-2013-471) and the Clinical and Translational Science Award program, funded by the National Center for Advancing Translational Sciences (grant UL1 TR000093) at the National Institutes of Health.

Duality of Interest. D.M.M. is on the advisory board for Insulet. R.P.W. is a consultant for Medtronic and receives research support from Novo Nordisk. B.A.B. is on medical advisory

¹Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA

²Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO

³School of Paediatrics and Child Health, The University of Western Australia, Perth, Australia

Corresponding author: Bruce A. Buckingham, buckingham@stanford.edu.

Received 12 June 2015 and accepted 13 July 2015.

Clinical trial reg. no. NCT02199028, clinicaltrials.gov.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Table 1—Accuracy analysis of sensors in normal tissue compared with sensors in lipohypertrophied tissue

| | Sensor in normal tissue | Sensor in lipohypertrophied tissue | P value |
|--|----------------------------|------------------------------------|---------|
| N of samples paired with reference meter value | 1,537 | 1,547 | — |
| Mean ARD | 14.6 ± 15.0% | 13.2 ± 14.3% | N/A§ |
| Median ARD | 11.0% (4.9, 19.3) | 10.0% (4.3, 17.2) | <0.001 |
| MAD for BG ≤70 mg/dL | 18 mg/dL (n = 48) | 15 mg/dL (n = 49) | 0.14 |
| Median ARD for BG ≥250 mg/dL | 9.6% (4.8, 16.4) (n = 334) | 9.8% (4.6, 15.8) (n = 341) | 0.44 |
| ±20 mg/dL for BG ≤80 mg/dL* | 66.4% (n = 104) | 71.4% (n = 105) | 0.34 |
| ±20% for BG >80 mg/dL† | 79.9% (n = 1,433) | 85.3% (n = 1,442) | 0.003 |
| Overall %20/20‡ | 79.0% | 81.8% | 0.051 |

Data are n, mean ± SD, or median (interquartile range [25th%, 75th%]), unless stated otherwise. *Proportion of all sensor values that were within ±20 mg/dL of reference meter value for BG ≤80 mg/dL. †Proportion of all sensor values that were within ±20% of reference meter value for BG >80 mg/dL. ‡Proportion of all sensor values that were within ±20 mg/dL of reference meter value for BG ≤80 mg/dL or within ±20% of reference meter value for BG >80 mg/dL. §Data not evenly distributed.

boards for Sanofi, Novo Nordisk, Becton Dickinson, Unomedical, and Medtronic and has received research grant and/or material support from Medtronic, Dexcom, LifeScan, Insulet, Bayer, Unomedical, and Tandem. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. D.J.D. contributed to the research, wrote the manuscript, contributed to the discussion, and reviewed and edited the manuscript. D.M.M., L.M., R.P.W., S.P., T.T.L., and B.A.B. contributed to the research and the discussion and reviewed and edited the manuscript. D.M.M. and B.A.B. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the

integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in poster form at the 74th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 13–17 June 2014.

References

1. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. *Diabetes Metab* 2013;39:445–453
2. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic

patients and predisposing factors. *Exp Clin Endocrinol Diabetes* 1996;104:106–110

3. Heinemann L. Insulin absorption from lipodystrophic areas: a (neglected) source of trouble for insulin therapy? *J Diabetes Sci Technol* 2010;4:750–753
4. DeSalvo DJ, Shanmugham S, Ly TT, Wilson DM, Buckingham BA. Accuracy evaluation of blood glucose monitoring systems in children on overnight closed-loop control. *J Diabetes Sci Technol* 2014;8:969–973
5. Heinemann L, Hirsch L, Hovorka R. Lipohypertrophy and the artificial pancreas: is this an issue? *J Diabetes Sci Technol* 2014;8:915–917